logo
  

Argenx Stock Up On Positive CHMP Opinion For Efgartigimod For GMG Patients In Europe

Dutch immunology company argenx SE (ARGX) announced Friday that efgartigimod has received positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency for the treatment of adult patients with Generalized Myasthenia Gravis or gMG in Europe.

Argenx shares were gaining more than 3 percent in Europe trading, and more than 1 percent in the pre-market activity on Nasdaq.

The company noted that CHMP has recommended European Commission approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized gMG who are anti-acetylcholine receptor or AChR antibody positive.

The positive opinion is based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures.

The EC is expected to make a decision on marketing authorization application within approximately 60 days following CHMP recommendation. The approval will be applicable to all 27 European Union Member States, in addition to Iceland, Norway and Liechtenstein.

The positive CHMP opinion is a scientific recommendation for marketing authorization, serving as a basis for the EC's final decision on argenx's application for efgartigimod.

Efgartigimod is the first-and-only approved FcRn blocker in the U.S. as VYVGART (efgartigimod alfa-fcab) for the treatment of adult gMG patients who are anti-AChR antibody positive and in Japan for those who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

argenx also plans to launch efgartigimod in Canada, China through its collaboration with Zai Lab, and select additional regions.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
RELATED NEWS
Follow RTT